Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Sidrah Shah, Rachelle Rachmat, Synthia Enyioma, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12628-12628
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Stergios Boussios, Elie Rassy, Michele Moschetta, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3888-3888
Open Access | Times Cited: 99
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
Antonios Revythis, Anu Limbu, Christos Mikropoulos, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 14, pp. 8577-8577
Open Access | Times Cited: 82
Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
Sidrah Shah, Alison Cheung, M Kutka, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 13, pp. 8113-8113
Open Access | Times Cited: 77
BRCA1 AND BRCA2 MUTATIONS TESTING IN PROSTATE CANCER: DETECTION IN FORMALIN FIXED PARAFFIN EMBEDDED (FFPE) AND BLOOD SAMPLES
Giuseppa Zannini, Gaetano Facchini, Marco De Sio, et al.
Pathology - Research and Practice (2025) Vol. 266, pp. 155803-155803
Open Access | Times Cited: 2
Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
Yameen Hamid, Rukhshana Dina Rabbani, Rakkan Afsara, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 802-802
Open Access | Times Cited: 2
Targeting PI3K/Akt signaling in prostate cancer therapy
Mehrdad Hashemi, Afshin Taheriazam, Padideh Daneii, et al.
Journal of Cell Communication and Signaling (2022) Vol. 17, Iss. 3, pp. 423-443
Open Access | Times Cited: 45
Inflammatory Cytokine: An Attractive Target for Cancer Treatment
Hyang‐Mi Lee, Hye-Jin Lee, Ji‐Eun Chang
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2116-2116
Open Access | Times Cited: 42
Exosomes in the Diagnosis and Treatment of Renal Cell Cancer
Stergios Boussios, Perry Devo, Iain C. A. Goodall, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14356-14356
Open Access | Times Cited: 40
Contemporary review of prognostic markers of prostate cancer from a pathologist perspective
Martin Eliáš, Jan Bouchal, Milan Král, et al.
Biomedical Papers (2025)
Open Access | Times Cited: 1
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
Belén Congregado, I. Rivero Belenchón, I. Osman, et al.
Biomedicines (2022) Vol. 10, Iss. 6, pp. 1416-1416
Open Access | Times Cited: 36
NPAS2 promotes aerobic glycolysis and tumor growth in prostate cancer through HIF-1A signaling
Shuaijun Ma, Y Chen, Penghe Quan, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma
Xiaofeng Cheng, Zhenhao Zeng, Heng Yang, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Natural product Pulsatilla saponin D sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair
Shengbin Lin, Binghe Sun, Yin Zhu, et al.
Journal of Pharmacy and Pharmacology (2025)
Closed Access
Multi-Omics Analysis of the Anoikis Gene CASP8 in Prostate Cancer and Biochemical Recurrence (BCR)
Shan Huang, Hang Yin
Biomedicines (2025) Vol. 13, Iss. 3, pp. 661-661
Open Access
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
Jinge Zhao, Bo Tang, Pengfei Shen, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104698-104698
Closed Access
PD-L1 expression in prostate cancer and Gleason Grade Group: is there any relationship? Findings from a multi-institutional cohort.
Vincenzo Fiorentino, Ludovica Pepe, Cristina Pizzimenti, et al.
Pathology - Research and Practice (2025), pp. 155916-155916
Open Access
Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective
Jekmal Malau, Siti Rohmah, Nanda Diva Meilani, et al.
Egyptian Journal of Medical Human Genetics (2025) Vol. 26, Iss. 1
Open Access
Race and prostate cancer: genomic landscape
Camilo Arenas‐Gallo, Jude Owiredu, Ilon Weinstein, et al.
Nature Reviews Urology (2022) Vol. 19, Iss. 9, pp. 547-561
Closed Access | Times Cited: 19
Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives
Paweł Kiełb, Kamil Kowalczyk, Adam Gurwin, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1552-1552
Open Access | Times Cited: 12
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States
Rana R. McKay, Alicia K. Morgans, Neal D. Shore, et al.
Cancer Treatment Reviews (2024) Vol. 126, pp. 102726-102726
Open Access | Times Cited: 4
Strategies for the prevention or reversal of PARP inhibitor resistance
Zahi Mitri, Shaun Goodyear, Gordon B. Mills
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 10, pp. 959-975
Open Access | Times Cited: 4
Role of lncRNA PVT1 in the progression of urological cancers: Novel insights into signaling pathways and clinical opportunities
Mehrdad Hashemi, Hamidreza Gholamrezaei, Faezeh Ziyaei, et al.
Cellular Signalling (2025), pp. 111736-111736
Closed Access
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer
Hiroko Kimura, Kei Mizuno, Masaki Shiota, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 9, pp. 1680-1690
Open Access | Times Cited: 16
Clinico-Pathological Factors Determining Recurrence of Phyllodes Tumors of the Breast: The 25-Year Experience at a Tertiary Cancer Centre
Baijaeek Sain, Arnab Gupta, Aruni Ghose, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 5, pp. 866-866
Open Access | Times Cited: 10
Novel signatures of prostate cancer progression and therapeutic resistance
Jason Wang, Reuben Ben‐David, Reza Mehrazin, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 12, pp. 1195-1206
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top